InnovAge Q3 revenue rises 15.5% but reports $29.9M net loss; raises 2026 revenue and EBITDA guidance

InnovAge reported a 15.5% revenue increase to $251.9 million for Q3 fiscal 2026, driven by improved center performance and investments in clinical and technology capabilities. Despite a net loss of $29.9 million, the company saw a 49.8% rise in center-level contribution margin and a significant increase in Adjusted EBITDA to $30.5 million. InnovAge raised its full-year 2026 revenue guidance to $950-$975 million and Adjusted EBITDA guidance to $85-$90 million, reflecting confidence in ongoing growth and operational improvements. The company serves approximately 8,050 participants across 20 centers in six states.